EyePoint Pharmaceuticals’ stock (EYPT) surged on Monday after the company announced promising interim data from its Phase 2 VERONA trial of Duravyu for diabetic macular edema (DME). The data revealed that Duravyu 2.7mg demonstrated early, sustained, and clinically meaningful improvements in visual acuity and anatomical control compared to Eylea, a leading treatment for DME. This positive news has investors optimistic about the future of Duravyu as a potential new treatment option for DME.
The Dow Jones Industrial Average climbed over 200 points on Monday, driven by strong gains in the healthcare and technology sectors. PROCEPT BioRobotics, Monte Rosa Therapeutics, and EyePoint Pharmaceuticals were among the top performers, fueled by positive financial results, licensing deals, and promising clinical trial data. Other notable movers include Revance Therapeutics, ImmunityBio, and Trump Media & Technology Group, while the Bitcoin surge boosted MicroStrategy and MARA Holdings.
Several notable insider trades occurred on Monday, despite the overall positive performance of U.S. stocks. These transactions provide insights into the perspectives of company insiders and can signal potential investment opportunities. Below are details of these insider purchases:
